{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:52:25Z","timestamp":1777711945413,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.12.035","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:13:45Z","timestamp":1671588825000},"page":"914-921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older"],"prefix":"10.1016","volume":"41","author":[{"given":"Esther","family":"Saiag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifat","family":"Alcalay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Or","family":"Marudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avi","family":"Orr-Urtreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7844","key":"10.1016\/j.vaccine.2022.12.035_b0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","article-title":"Age-specific mortality and immunity patterns of SARS-CoV-2","volume":"590","author":"O'Driscoll","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.035_b0010","doi-asserted-by":"crossref","first-page":"e657","DOI":"10.1002\/hsr2.657","article-title":"COVID-19 mortality and its predictors in the elderly: a systematic review","volume":"5","author":"Dadras","year":"2022","journal-title":"Health Sci Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.035_b0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13054-021-03551-3","article-title":"The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study","volume":"25","author":"Jung","year":"2021","journal-title":"Crit Care"},{"key":"10.1016\/j.vaccine.2022.12.035_b0020","doi-asserted-by":"crossref","unstructured":"Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020;370(6515). doi: 10.1126\/science.abd4585. Epub 2020 Sep 2doi: eabd4585 [pii].","DOI":"10.1126\/science.abd4585"},{"key":"10.1016\/j.vaccine.2022.12.035_b0025","doi-asserted-by":"crossref","unstructured":"Bastard P, Gervais A, Le Voyer T, et al. Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths. Sci Immunol. 2021;6(62). doi: 10.1126\/sciimmunol.abl4340. doi: eabl4340 [pii].","DOI":"10.1126\/sciimmunol.abl4340"},{"key":"10.1016\/j.vaccine.2022.12.035_b0030","article-title":"The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies","author":"Manry","year":"2022","journal-title":"Res Sq"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.035_b0035","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1038\/s41598-018-28111-8","article-title":"Age-related differences in humoral and cellular immune responses after primary immunisation: Indications for stratified vaccination schedules","volume":"8","author":"Wagner","year":"2018","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.vaccine.2022.12.035_b0040","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","article-title":"Influence of immune aging on vaccine responses","volume":"145","author":"Gustafson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.12.035_b0045","doi-asserted-by":"crossref","unstructured":"Boraschi D, Aguado MT, Dutel C, et al. The gracefully aging immune system. Sci Transl Med 2013;5(185):185ps8. doi: 10.1126\/scitranslmed.3005624 [doi].","DOI":"10.1126\/scitranslmed.3005624"},{"issue":"25","key":"10.1016\/j.vaccine.2022.12.035_b0050","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2005.01.085","article-title":"Insufficient protection for healthy elderly adults by tetanus and TBE vaccines","volume":"23","author":"Hainz","year":"2005","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2022.12.035_b0055","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1016\/j.vaccine.2010.03.024","article-title":"Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50\u201390 years","volume":"28","author":"Weinberger","year":"2010","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.12.035_b0060","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.035_b0065","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41467-022-29225-4","article-title":"Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors","volume":"13","author":"Perez-Alos","year":"2022","journal-title":"Nat Commun"},{"issue":"7872","key":"10.1016\/j.vaccine.2022.12.035_b0070","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.12.035_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.758294","article-title":"The impact of age difference on the efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.12.035_b0080","doi-asserted-by":"crossref","unstructured":"Lee HK, Knabl L, Knabl L, et al. Robust immune response to the BNT162b mRNA vaccine in an elderly population vaccinated 15 months after recovery from COVID-19. medRxiv. 2021. doi: 2021.09.08.21263284 [pii].","DOI":"10.1101\/2021.09.08.21263284"},{"issue":"14","key":"10.1016\/j.vaccine.2022.12.035_b0085","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of covid-19 mRNA vaccine against omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.vaccine.2022.12.035_b0090","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a fourth dose of BNT162b2 against omicron in israel","volume":"386","author":"Bar-On","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.12.035_b0095","unstructured":"Arbel R, Sergienko R, Friger M, et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med."},{"key":"10.1016\/j.vaccine.2022.12.035_b0100","doi-asserted-by":"crossref","first-page":"e071113","DOI":"10.1136\/bmj-2022-071113","article-title":"Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in israel: retrospective, test negative, case-control study","volume":"377","author":"Gazit","year":"2022","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.vaccine.2022.12.035_b0105","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1056\/NEJMoa2201688","article-title":"Fourth dose of BNT162b2 mRNA covid-19 vaccine in a nationwide setting","volume":"386","author":"Magen","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.035_b0110","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jaci.2021.05.029","article-title":"Immunogenicity of pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity","volume":"148","author":"Hagin","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.035_b0115","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2666-7568(21)00282-8","article-title":"Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): Prospective cohort study in england","volume":"3","author":"Krutikov","year":"2022","journal-title":"Lancet Healthy longevity"},{"key":"10.1016\/j.vaccine.2022.12.035_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.104765","article-title":"Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection","volume":"136","author":"Van Elslande","year":"2021","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2022.12.035_b0125","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.035_b0130","doi-asserted-by":"crossref","unstructured":"Edara V, Manning KE, Ellis M, et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. bioRxiv: the preprint server for biology. 2021.","DOI":"10.1101\/2021.12.20.473557"},{"key":"10.1016\/j.vaccine.2022.12.035_b0135","doi-asserted-by":"crossref","unstructured":"Sievers BL, Chakraborty S, Xue Y, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against beta and omicron pseudoviruses. Sci Transl Med 2022;14(634):eabn7842.","DOI":"10.1126\/scitranslmed.abn7842"},{"issue":"7","key":"10.1016\/j.vaccine.2022.12.035_b0140","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.vaccine.2022.12.035_b0145","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"issue":"11","key":"10.1016\/j.vaccine.2022.12.035_b0150","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/s41423-021-00767-9","article-title":"T cell immune responses to SARS-CoV-2 and variants of concern (alpha and delta) in infected and vaccinated individuals","volume":"18","author":"Jordan","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.035_b0155","article-title":"Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients","volume":"1","author":"Thieme","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2022.12.035_b0160","doi-asserted-by":"crossref","DOI":"10.1177\/11779322211025876","article-title":"Structure and function of major SARS-CoV-2 and SARS-CoV proteins","volume":"15","author":"Gorkhali","year":"2021","journal-title":"Bioinform Biol Insights"},{"issue":"9","key":"10.1016\/j.vaccine.2022.12.035_b0165","doi-asserted-by":"crossref","first-page":"e1009842","DOI":"10.1371\/journal.ppat.1009842","article-title":"Broadly directed SARS-CoV-2-specific CD4 T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19","volume":"17","author":"Heide","year":"2021","journal-title":"PLoS Pathog"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:29Z","timestamp":1759404089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22015602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22015602"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}